Dyne Therapeutics (DYN) PT Lowered to $36 at Morgan Stanley

September 9, 2026 7:54 AM

Morgan Stanley analyst Michael E Ulz lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $36.00 (from $45.00) while maintaining a Overweight rating.

No results found